DBV Technologies provided an organizational update, which included appointing David Schilansky as Chief Operating Officer, Bertrand Dupont as Senior Executive Vice President, Technology, Charles Ruban as Senior Executive Vice President, Clinical Development & North American Operations and Laurent Martin as Senior Executive Vice President, Product Strategy & Regulatory Affairs. This new corporate organization reflects DBV's focus to become the leader in discovering, developing and commercializing food allergy treatments, while leveraging its Viaskin platform to develop innovative immunotherapy products. David Schilansky, previously Chief Financial Officer, has been appointed by the Board as Chief Operating Officer to support the CEO in the implementation of DBV's strategy.

Bertrand Dupont, previously Chief Technical Officer, has been appointed as Senior Executive Vice President, Technology, and will be in charge of the continued development of the electrospray and upscaling of the production tools. Mr. Dupont will report to the CEO. Charles Ruban, Chief Development Officer, has been appointed Senior Executive Vice President, Clinical Development & North American Operations, permanently relocating to New York, NY mid-2015 to oversee DBV Technologies Inc., the company's US subsidiary.

Mr. Ruban will lead DBV's launch-readiness effort for Viaskin Peanut, while overseeing DBV's Global Clinical Operations, Strategic Marketing, Market Access and Medical Affairs teams. Mr. Ruban will oversee late stage development while accelerating and maximizing Viaskin's access to the market. Mr. Ruban will report to the CEO. Laurent Martin, Director of Regulatory Affairs & Quality, will be appointed Senior Executive Vice President, Product Strategy & Regulatory Affairs, tasked with executing DBV's regulatory strategy and defining the path forward in food allergy.

Mr. Martin will supervise project management of all food allergy programs. Laurent's new functions will be effective mid-2015 and will report to the CEO.